Day One Biopharmaceuticals to Acquire Mersana Therapeutics
I'm PortAI, I can summarize articles.
Day One Biopharmaceuticals has announced a definitive merger agreement to acquire Mersana Therapeutics, enhancing its portfolio with the antibody-drug conjugate emiltatug ledadotin (Emi-Le), currently in Phase 1 trials for adenoid cystic carcinoma type-1. The deal includes a tender offer of $25 per share in cash, plus potential milestone payments, totaling up to $55.25 per share, with an overall deal value of approximately $285 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments